Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors

  • Mark A Giembycz
  • Current Opinion in Pharmacology, June 2005, Elsevier
  • DOI: 10.1016/j.coph.2005.04.001

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1016/j.coph.2005.04.001

The following have contributed to this page: Dr Mark giembycz